Abstract 1235
Background
Uveal Melanoma (UVM) is the most common ocular malignancy. Many mutations were identified in affected patients defining genetic predisposition syndromes. Previous studies discussed separately the incidence of single or second primary ocular melanomas. However, understanding the genetic background, and relation to other tumors requires further investigation for defining the UVM subgroups, their shared developmental and, hence, the targeting mechanisms.
Methods
We used Surveillance Epidemiology and End Results program of the National Cancer Institute, United States, to review patients diagnosed with UVM, either as single primary or combined with other malignancies, between 1973 and 2015. We have calculated standardized incidence ratios (SIR) and measured risk in the form of Observed/Expected ratios (O/E) and Hazard Ratios (HR).
Results
We have identified 7,386 patients diagnosed with single primary UVM, besides 646 with UVM followed by another malignancy and 437 patients diagnosed with a primary UVM after other malignancies. SIR of developing another malignancy following UVM was significant and increased most within the first 5 years following UVM following choroid uveal melanoma (1.198, 95%CI=1.056-1.353). The risk of developing melanomas of the skin, thyroid cancers, and kidney cancers, increased significantly within the first 5 years following UVM, with SIRs (3.763, 95%CI=2.539-5.372), (3.158, 95%CI=1.270-6.506), and (2.618, 95%CI=1.465-4.317), respectively. SIR of developing a second UVM following another malignancy was significant between the 5th and 10th years following the first cancer diagnosis (O/E=1.204, 95% CI = 1.007-1.428), where the increase of UVM risk was highest among patients with primary prostate cancer (1.404, 95%CI=1.024-1.878) or leukemia (2.915, 95%CI=1.070-6.345). Cox models did not show a significant difference between the overall survival of single UVM and second UVM, but females showed better overall survival outcomes. In addition, Ciliary body tumors, and dark-skinned people were associated with worse survival outcomes.
Conclusions
The three groups of uveal melanoma showed different behaviors that may represent diverse underlying developmental mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3517 - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).
Presenter: Bert Van Den Heuvel
Session: Poster Display session 3
Resources:
Abstract
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract